ReviewJournal of personalized medicine2019
Precision Oncology-The Quest for Evidence.
Review in Journal of personalized medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Malignant Melanoma: Landscape of Molecular Markers.Biomedicines · 2026Article
- The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines.Current oncology reports · 2025Article
- Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer.ESMO gastrointestinal oncology · 2024Article
- A brief reference to AI-driven audible reality (AuRa) in open world: potential, applications, and evaluation.Frontiers in artificial intelligence · 2024Article
- Feasibility of Precision Medicine in Hypertension Management-Scope and Technological Aspects.Journal of personalized medicine · 2022Article
- A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada.NPJ precision oncology · 2022Review
- Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring.Healthcare (Basel, Switzerland) · 2022Article
- Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports.CPT: pharmacometrics & systems pharmacology · 2022Review
- Stakeholder Perspectives on Navigating Evidentiary and Decision Uncertainty in Precision Oncology.Journal of personalized medicine · 2022Article
- Clinical and cost outcomes following genomics-informed treatment for advanced cancers.Cancer medicine · 2021Article
- Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.Pharmaceuticals (Basel, Switzerland) · 2021Article
- The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?Translational oncology · 2021Review
- From Medical Imaging to Radiomics: Role of Data Science for Advancing Precision Health.Journal of personalized medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The molecular characterization of patient tumors provides a rational and highly promising approach for guiding oncologists in treatment decision-making. Notwithstanding, genomic medicine still remains in its infancy, with innovators and early adopters continuing to carry a significant portion of the clinical and financial risk. Numerous innovative precision oncology trials have emerged globally to address the associated need for evidence of clinical utility. These studies seek to capitalize on the power of predictive biomarkers and/or treatment decision support analytics, to expeditiously and cost-effectively demonstrate the positive impact of these technologies on drug resistance/response, patient survival, and/or quality of life. Here, we discuss the molecular foundations of these approaches and highlight the diversity of innovative trial strategies that are capitalizing on this emergent knowledge. We conclude that, as increasing volumes of clinico-molecular outcomes data become available, in future, we will begin to transition away from expert systems for treatment decision support (TDS), towards the power of AI-assisted TDS-an evolution that may truly revolutionize the nature and success of cancer patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.